Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 6/20 | 0.46 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.42 |
| ▸ | GPR6 | P46095 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 4/20 | 0.41 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.40 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL402545 | 0.93 | ALDH1A1 (0.43) | CHEK1ALDH1A1 | |
| SCHEMBL402376 | 0.91 | PRKAA2 (0.40) | CHEK1PRKAA2GPR6FAAHKCNQ3 | |
| SCHEMBL398486 | 0.91 | KDR (0.43) | CHEK1PRKAA2ALDH1A1FAAHKCNQ3 | |
| SCHEMBL402377 | 0.91 | CHEK1 (0.39) | CHEK1PRKAA2ALDH1A1FAAHKCNQ3 | |
| SCHEMBL3207863 | 0.90 | FAAH (0.42) | CHEK1PRKAA2FAAHKCNQ3KCNQ2 | |
| SCHEMBL400684 | 0.87 | PIK3CA (0.44) | PRKAA2GPR6FAAHPIK3CDPIK3CA | |
| SCHEMBL402283 | 0.87 | CHEK1 (0.51) | CHEK1PRKAA2GPR6ALDH1A1CYP3A4 | |
| SCHEMBL401754 | 0.86 | FAAH (0.53) | PRKAA2FAAH | |
| SCHEMBL402841 | 0.85 | PRKAA2 (0.47) | PRKAA2FAAHPIK3CDPIK3CAPIK3CB | |
| SCHEMBL402943 | 0.84 | PIK3CA (0.44) | PRKAA2FAAHPIK3CDPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198203-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED | 2021-07-01 | — | — | US | claimed |
| US-20190352267-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED | 2019-11-21 | — | — | US | claimed |
| US-20180305316-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED | 2018-10-25 | — | — | US | claimed |
| EP-2862859-A2 | Compounds, compositions and methods | Cytokinetics, Inc. (US) | 2015-04-22 | — | — | EP | claimed |
| US-20150005296-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED | 2015-01-01 | — | — | US | claimed |
| US-20090036447-A1 | Compounds, Compositions and Methods | CYTOKINETICS, INC. (US) | 2009-02-05 | — | — | US | claimed |
| US-20060014761-A1 | Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate | CYTOKINETICS, INCORPORATED | 2006-01-19 | — | — | US | claimed |
| US-12264133-B2 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED (US) | 2025-04-01 | — | — | US | disclosed |
| US-20220185779-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED | 2022-06-16 | — | — | US | disclosed |
| US-10975034-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| US-20190352267-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED | 2019-11-21 | — | — | US | disclosed |
| US-10385023-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2019-08-20 | — | — | US | disclosed |
| US-20180305316-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED | 2018-10-25 | — | — | US | disclosed |
| EP-1959960-B1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS INC (US) | 2013-04-10 | — | — | EP | disclosed |
| US-20120172372-A1 | Ureas and Their Use in the Treatment of Heart Failure | CYTOKINETICS, INC. | 2012-07-05 | — | — | US | disclosed |
| US-8101617-B2 | Disubstituted ureas and uses thereof in treating heart failure | AMGEN, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20090099198-A1 | Compounds, Compositions and Methods | CYTOKINETICS, INC. | 2009-04-16 | — | — | US | disclosed |
| US-7507735-B2 | Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate | CYTOKINETICS, INC. (US) | 2009-03-24 | — | — | US | disclosed |
| US-20090036447-A1 | Compounds, Compositions and Methods | CYTOKINETICS, INC. (US) | 2009-02-05 | — | — | US | disclosed |
| US-20060014761-A1 | Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate | CYTOKINETICS, INCORPORATED | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172372-A1 | Ureas and Their Use in the Treatment of Heart Failure | TNNI3, TNNT2, MYLK2 | CHEK1 2874/4885PRKAA2 2151/4885GPR6 4106/4885 |
| US-20060014761-A1 | Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate | TNNI3, MYLK2, TNNT2 | CHEK1 2918/4885PRKAA2 658/4885GPR6 2980/4885 |
| US-10385023-B2 | Compounds, compositions and methods | TNNI3, TNNC1, TNNT2 | CHEK1 2194/4885PRKAA2 1298/4885GPR6 4028/4885 |
| US-20220185779-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | TNNI3, TNNC1, TNNT2 | CHEK1 2194/4885PRKAA2 1298/4885GPR6 4028/4885 |
| US-12264133-B2 | Compounds, compositions and methods | TNNI3, TNNC1, TNNT2 | CHEK1 2194/4885PRKAA2 1298/4885GPR6 4028/4885 |
| US-20090099198-A1 | Compounds, Compositions and Methods | TNNI3, TNNC1, TNNT2 | CHEK1 2194/4885PRKAA2 1298/4885GPR6 4028/4885 |
| US-20190352267-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | TNNI3, TNNC1, TNNT2 | CHEK1 2194/4885PRKAA2 1298/4885GPR6 4028/4885 |
| US-20150005296-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | TNNI3, TNNC1, TNNT2 | CHEK1 2194/4885PRKAA2 1298/4885GPR6 4028/4885 |
| US-10975034-B2 | Compounds, compositions and methods | TNNI3, TNNC1, TNNT2 | CHEK1 2194/4885PRKAA2 1298/4885GPR6 4028/4885 |
| US-20090036447-A1 | Compounds, Compositions and Methods | TNNI3, TNNC1, TNNT2 | CHEK1 2194/4885PRKAA2 1298/4885GPR6 4028/4885 |
| US-20180305316-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | TNNI3, TNNC1, TNNT2 | CHEK1 2194/4885PRKAA2 1298/4885GPR6 4028/4885 |
| US-20210198203-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | TNNI3, TNNC1, TNNT2 | CHEK1 2194/4885PRKAA2 1298/4885GPR6 4028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.